First human tests begin for new oral drug LY3502970

NCT ID NCT03929744

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early-stage study evaluates the safety and how the body handles LY3502970, an experimental oral drug, in healthy adults. Participants receive either a single dose or multiple doses of the drug or a placebo. The study does not aim to treat any medical condition but gathers essential safety and drug-level information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3502970
What this could lead to: If safe and well-tolerated, LY3502970 could be developed further for conditions like diabetes or obesity.
What could go wrong: This is an early phase 1 study in healthy people, so it cannot show whether the drug works for any disease. Side effects are possible and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Locations

Covance Dallas

Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.